BeOne Medicines AG

NasdaqGS:ONC Stock Report

Market Cap: US$40.5b

BeOne Medicines Past Earnings Performance

Past criteria checks 3/6

BeOne Medicines has been growing earnings at an average annual rate of 25%, while the Biotechs industry saw earnings growing at 22.8% annually. Revenues have been growing at an average rate of 42% per year. BeOne Medicines's return on equity is 1.7%, and it has net margins of 1.4%.

Key information

24.98%

Earnings growth rate

29.32%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate41.98%
Return on equity1.66%
Net Margin1.38%
Last Earnings Update30 Sep 2025

Recent past performance updates

We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve

Recent updates

We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve

Nov 14
We Think BeOne Medicines' (NASDAQ:ONC) Profit Is Only A Baseline For What They Can Achieve

BeOne Medicines: Sonrotoclax Could Set Next Stage Of Growth For Hematology Pipeline

Oct 14

Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why

May 15
Shareholders Would Not Be Objecting To BeiGene, Ltd.'s (NASDAQ:ONC) CEO Compensation And Here's Why
User avatar

US Facility And Phase III Trials Will Expand Markets

Expansion of manufacturing capabilities and global market presence aims to boost revenue and market share, particularly in B-cell malignancies.

Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?

Apr 23
Is BeiGene (NASDAQ:ONC) Weighed On By Its Debt Load?

BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025

Feb 28

BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Feb 06
BeiGene, Ltd. (NASDAQ:ONC) Stock Catapults 26% Though Its Price And Business Still Lag The Industry

Is BeiGene (NASDAQ:ONC) A Risky Investment?

Jan 14
Is BeiGene (NASDAQ:ONC) A Risky Investment?

BeiGene: Nearing Profitability On TEVIMBRA Approval In The EU And US

Dec 01

BeiGene: TEVIMBRA European Push Continues With Positive CHMP Opinion

Nov 06

BeiGene: Poised For Re-Rating As BTKi Sales Show Strong Beat

Aug 22

BeiGene: Navigating Patent Disputes Towards Profitability (Rating Upgrade)

Jun 21

Revenue & Expenses Breakdown

How BeOne Medicines makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:ONC Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 254,973692,0322,072
30 Jun 254,562-1781,9582,045
31 Mar 254,176-3921,8641,975
31 Dec 243,810-6451,8321,953
30 Sep 243,306-8221,7191,882
30 Jun 243,097-5241,6561,862
31 Mar 242,763-7841,6081,831
31 Dec 232,459-8821,5091,779
30 Sep 232,143-9761,4022,897
30 Jun 231,811-1,7321,3762,472
31 Mar 231,557-1,9171,3132,049
31 Dec 221,416-2,0041,2791,641
30 Sep 221,250-2,1491,2570
30 Jun 221,069-2,0301,2030
31 Mar 22877-1,9601,1040
31 Dec 211,176-1,4589901,459
30 Sep 211,062-1,3408920
30 Jun 21947-1,3277830
31 Mar 21863-1,1676750
31 Dec 20309-1,6256000
30 Sep 20266-1,5125350
30 Jun 20225-1,3944790
31 Mar 20402-1,1454380
31 Dec 19428-9493880
30 Sep 19430-8293170
30 Jun 19434-6652610
31 Mar 19244-7372240
31 Dec 18198-6741950
30 Sep 18158-5051500
30 Jun 18324-2431170
31 Mar 18271-147830
31 Dec 17238-93630
30 Sep 17220-3144-5
30 Jun 170-184330
31 Mar 170-148260
31 Dec 161-119200
30 Sep 166-109155
30 Jun 167-87120
31 Mar 168-6990
31 Dec 159-5770
30 Sep 156-3460
30 Jun 1511-2980
31 Mar 1512-2670
31 Dec 1413-1870

Quality Earnings: ONC has high quality earnings.

Growing Profit Margin: ONC became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: ONC has become profitable over the past 5 years, growing earnings by 25% per year.

Accelerating Growth: ONC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: ONC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (52.4%).

Return on Equity

High ROE: ONC's Return on Equity (1.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/16 03:12
End of Day Share Price 2025/11/14 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BeOne Medicines AG is covered by 67 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tianli WenAletheia Analyst Network Limited
Brian SkorneyBaird
Peter LawsonBarclays